{Reference Type}: Journal Article
{Title}: Resmetirom for treatment of MASH.
{Author}: Sookoian S;Pirola CJ;
{Journal}: Cell
{Volume}: 187
{Issue}: 12
{Year}: 2024 Jun 6
{Factor}: 66.85
{DOI}: 10.1016/j.cell.2024.05.009
{Abstract}: Resmetirom is an oral selective THR-β agonist conditionally approved for the treatment of patients with noncirrhotic MASH with moderate to advanced fibrosis. Resmetirom restores mitochondrial and hepatic metabolic function; reduces atherogenic lipids; improves hepatic steatosis, inflammation, and fibrosis; and has no significant effect on THR-α. To view this Bench to Bedside, open or download the PDF.